Jacqueline Maaloufová

High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis

Tomáš Kozák, Eva Havrdová, Jiří Piťha et al. · Bone Marrow Transplantation · 2000 · 109 citations

High-dose Immunosuppressive Therapy, Autoimmune Disease, Immunosuppressive Therapy +11

Prognostic impact of <i>DNMT3A</i> mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia

Jana Marková, Petra Michková, Kateřina Burčková et al. · European Journal Of Haematology · 2011 · 72 citations

Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?

Z Sieglová, Soňa Žilovcová, Jaroslav Čermák et al. · Leukemia Research · 2004 · 68 citations

Hematological Malignancy, Chromatin, Genome Instability +12

CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma

Ota Fuchs, Dana Provazníková, Marcela Kocova et al. · Blood Cells Molecules and Diseases · 2008 · 49 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +10

Monitoring of minimal residual disease in patients with core binding factor acute myeloid leukemia and the impact of<i>C-KIT</i>,<i>FLT3</i>, and<i>JAK2</i>mutations on clinical outcome

Jana Marková, Jana Marková, Zuzana Jirakova Trnkova et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2009 · 34 citations